Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis

Bibliographic Details
Main Authors:	Ashley Elliott, Gary Wright
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-06-01
Series:	Therapeutic Advances in Musculoskeletal Disease
Online Access:	https://doi.org/10.1177/1759720X19858510

Similar Items

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis
by: Ahmet Karataş, et al.
Published: (2020-10-01)

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis
by: Sumera Ghani, et al.
Published: (2023-06-01)

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
by: Francesco Molica Colella, et al.
Published: (2023-03-01)

Effects of TNF-α inhibition secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis
by: Ashley Elliott, et al.
Published: (2023-11-01)

Role of secukinumab in ankylosing spondylitis with tubercular uveitis
by: Padmamalini Mahendradas, et al.
Published: (2020-01-01)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
by: Juan José Alegre-Sancho, et al.
Published: (2023-11-01)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
by: Colombo GL, et al.
Published: (2018-08-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Features of medical and social expertise in ankylosing spondylitis and psoriatic arthritis
by: T. V. Dubinina, et al.
Published: (2023-02-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
by: Maria G. Tektonidou, et al.
Published: (2020-09-01)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
by: A. Deodhar, et al.
Published: (2019-05-01)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
by: Coates, LC, et al.
Published: (2023)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS
by: Emery, P, et al.
Published: (2012)

Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset
by: Sarah B. Lieber, et al.
Published: (2022-04-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis
by: Krzysztof Bonek, et al.
Published: (2022-01-01)

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
by: Purmonen T, et al.
Published: (2019-02-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01)

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
by: Peter Nash, et al.
Published: (2023-10-01)

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
by: Gia Deyab, et al.
Published: (2017-01-01)

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry
by: Alba Erra, et al.
Published: (2022-11-01)

Treatment of psoriatic arthritis with secukinumab: a case series
by: Stefania Nicola, et al.
Published: (2018-11-01)

Treatment with secukinumab in multi-comorbid patients with psoriatic arthritis
by: Ombretta Viapiana, et al.
Published: (2018-12-01)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
by: Alice B. Gottlieb, et al.
Published: (2022-04-01)

Impact of biological and non-biological treatment on hematological indices in patients with ankylosing spondylitis and psoriatic arthritis
by: Fatma Mohammed Aboud, et al.
Published: (2023-03-01)

Specific features of axial spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, in persons of different genders
by: A. P. Rebrov, et al.
Published: (2015-03-01)

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
by: Andrea Rubbert-Roth, et al.
Published: (2023-11-01)

Successful Treatment of SAPHO Syndrome Complicated with Ankylosing Spondylitis by Secukinumab: A Case Report
by: Wei Tu, et al.
Published: (2023-03-01)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
by: Sara Alonso, et al.
Published: (2021-05-01)

THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE
by: artilce Editorial
Published: (2017-04-01)

THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE
by: artilce Editorial
Published: (2017-01-01)

Is secukinumab effective for psoriatic arthritis with insufficient response to initial treatment?
by: Soledad Venegas-Iribarren, et al.
Published: (2017-12-01)

EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS
by: Van Laar, J, et al.
Published: (2012)

Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
by: Krzysztof Bonek, et al.
Published: (2022-04-01)

Complications of primary total hip arthroplasty among patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and primary osteoarthritis
by: Qiang Lian, et al.
Published: (2022-10-01)

Maternal Interleukin-17 and disease activity influence pregnancy outcomes in women with psoriatic arthritis and ankylosing spondylitis
by: Ehab F. Girbash, et al.
Published: (2023-01-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)